Scholar Rock Holding Co. (NASDAQ:SRRK – Get Free Report) CFO Edward H. Myles sold 12,539 shares of the company’s stock in a transaction dated Thursday, January 16th. The stock was sold at an average price of $44.20, for a total value of $554,223.80. Following the sale, the chief financial officer now owns 148,549 shares in the company, valued at approximately $6,565,865.80. This trade represents a 7.78 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Scholar Rock Stock Up 4.1 %
Scholar Rock stock opened at $46.73 on Thursday. The company has a market capitalization of $4.37 billion, a P/E ratio of -19.89 and a beta of 0.52. The company has a debt-to-equity ratio of 0.63, a quick ratio of 3.88 and a current ratio of 3.88. Scholar Rock Holding Co. has a fifty-two week low of $6.76 and a fifty-two week high of $46.81. The stock has a 50-day simple moving average of $40.33 and a 200-day simple moving average of $23.75.
Institutional Investors Weigh In On Scholar Rock
Several large investors have recently modified their holdings of SRRK. Wellington Management Group LLP boosted its stake in Scholar Rock by 16.2% during the 3rd quarter. Wellington Management Group LLP now owns 199,777 shares of the company’s stock worth $1,600,000 after purchasing an additional 27,801 shares during the period. Charles Schwab Investment Management Inc. boosted its stake in shares of Scholar Rock by 9.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 502,793 shares of the company’s stock worth $4,027,000 after buying an additional 42,139 shares during the period. Barclays PLC grew its holdings in shares of Scholar Rock by 103.4% during the third quarter. Barclays PLC now owns 165,449 shares of the company’s stock worth $1,324,000 after buying an additional 84,118 shares during the last quarter. Clearbridge Investments LLC purchased a new stake in Scholar Rock during the 2nd quarter valued at approximately $6,223,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Scholar Rock by 7.1% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 94,795 shares of the company’s stock valued at $759,000 after acquiring an additional 6,269 shares during the last quarter. 91.08% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Read Our Latest Report on SRRK
About Scholar Rock
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.
Featured Articles
- Five stocks we like better than Scholar Rock
- The 3 Best Blue-Chip Stocks to Buy Now
- Oracle Announces Game-Changing News for the AI Industry
- What Investors Need to Know to Beat the Market
- Netflix Adds 19 Million Subscribers, Growth Is Far From Over
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Tempus AI: A Game-Changer in AI-Powered Healthcare
Receive News & Ratings for Scholar Rock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scholar Rock and related companies with MarketBeat.com's FREE daily email newsletter.